Skip to main content

Research Repository

Advanced Search

Outputs (40)

The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study (2024)
Journal Article
Zelenetz, A. D., Jurczak, W., Ribrag, V., Linton, K., Collins, G. P., Jiménez, J. L., Bishton, M., Dholaria, B., Mengarelli, A., Phillips, T. J., Sungala, N., Musuraca, G., Sheehy, O., Van Den Neste, E., Odera, M., Miao, L., Gold, D. P., Ghalie, R. G., & Zinzani, P. L. (2024). The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. HemaSphere, 8(8), Article e138. https://doi.org/10.1002/hem3.138

In this global phase 2 study in patients with relapsed/refractory follicular lymphoma (FL), zandelisib was administered on intermittent dosing to mitigate immune‐related adverse events and infections that have been reported with oral PI3Kδ inhibitors... Read More about The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020 (2024)
Journal Article
Liu, H., Stanworth, S. J., McPhail, S., Bishton, M., Rous, B., Bacon, A., & Coats, T. (2024). Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020. Blood Advances, 8(17), 4593-4605. https://doi.org/10.1182/bloodadvances.2024013102

We report 1- and 5-year survival following AML diagnosis and early mortality, within 30 days of systemic anti-cancer therapy (SACT) treatments, using national cancer registry data in England.

Patients aged 18-99 years diagnosed between 2013 and 2... Read More about Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020.

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial (2024)
Journal Article
McIlroy, G., Lax, S., Gaskell, C., Jackson, A., Rhodes, M., Seale, T., Fox, Hopkins, L., Okosun, J., Barrington, S. F., Ringshausen, I., Ramsay, A. G., Calaminici, Linton, K., & Bishton, M. (2024). Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. BMC Cancer, 24, Article 370. https://doi.org/10.1186/s12885-024-12112-0

Background
Relapsed or refractory follicular lymphoma (rrFL) is an incurable disease associated with shorter remissions and survival after each line of standard therapy. Many promising novel, chemotherapy-free therapies are in development, but few a... Read More about Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.

Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma (2024)
Journal Article
Bishton, M. J., Crooks, C. J., Card, T. R., & West, J. (2024). Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma. British Journal of Haematology, 204(6), 2222-2226. https://doi.org/10.1111/bjh.19371

To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linke... Read More about Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.

Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline (2023)
Journal Article
Cox, M. F., Mackenzie, S., Low, R., Brown, M., Sanchez, E., Carr, A., Carpenter, B., Bishton, M., Duncombe, A., Akpabio, A., Kulasekararaj, A., Sin, F. E., Jones, A., Kavirayani, A., Sen, E. S., Quick, V., Dulay, G. S., Clark, S., Bauchmuller, K., Tattersall, R. S., & Manson, J. J. (2024). Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. The Lancet Rheumatology, 6(1), e51-e62. https://doi.org/10.1016/s2665-9913%2823%2900273-4

Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome characterised by persistently activated cytotoxic lymphocytes and macrophages, which, if untreated, leads to multiorgan dysfunction and death. HLH should be considered in any a... Read More about Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline.

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., Fox, C. P., Bishton, M., Pender, A., Gleeson, M., Cunningham, D., Davies, A. J., Yadollahi, S., Eyre, T. A., Collins, G. P., Djebbari, F., Kassam, S., Garland, P., Watts, E., Osborne, W., …Linton, K. M. (2024). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom (2023)
Journal Article
Minson, A., Hamad, N., Di Ciaccio, P., Talaulikar, D., Ku, M., Ratnasingam, S., Cheah, C., Yannakou, C. K., Bishton, M., Ng, Z. Y., Agrawal, S., McQuillan, A., Johnston, A., Choong, E., Wong, K., McQuillan, J., Beekman, A., Hawkes, E., & Dickinson, M. (2024). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology, 204(2), 548-554. https://doi.org/10.1111/bjh.19179

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma characterised by a heterogeneous clinical course. Patients can often receive sequential treatments, yet these typically yield diminishing periods of disease control, raising questions about... Read More about Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.

Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline (2023)
Journal Article
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M., Menon, G., Iyengar, S., Lewis, D., Lambert, J., Linton, K. M., McKay, P., & Haemato-Oncology Task Force of the British Society for Haematology, H.-O. T. F. O. T. B. S. F. H. (2024). Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline. British Journal of Haematology, 204(1), 108-126. https://doi.org/10.1111/bjh.19131

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., Cwynarski, K., Bishton, M. J., Fox, C. P., Hawkes, E. A., Maurer, M. J., El-Galaly, T. C., Cheah, C. Y., Bobillo, S., Caporn, P. L., Van Zyl, J., Klanova, M., Trněny, M., Puckrin, R., Stewart, D. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE
CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.